ArticleMolecular biology reports2026
Illuminating the pleiotropic effects of bixin-loaded nanoemulsion on glioblastoma cell behavior through an integrated approach.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma is a pervasive brain cancer characterized by extreme aggressiveness and death rates. The high fatality rate of GBM is accentuating the need for efficient natural alternatives, such as bixin. Bixin is an apocarotenoid abundant in Bixa orellana L. Despite its prominent coloring potential, the structural distinctiveness and remarkable antioxidant potential confer bixin therapeutic efficacy in ameliorating cancers in experimental models. Therefore, the present study developed a bixin-loaded nanoemulsion (BNE) to investigate the pleiotropic effects of bixin on GBM. METHODS AND
resultsAn integrated approach comprising in-vitro and in-silico analyses was adopted to elucidate the pharmaceutical potential of bixin in targeting key signaling molecules involved in proliferation, migration, and invasion. Interestingly, BNE suppressed the proliferation of GB cells in a concentration-dependent manner. Furthermore, BNE curbed the invasion and migration of Ln-229 cells, as evidenced in migration and invasion assays. BNE downregulated the expression of cortactin, a key protein involved in the invadopodia formation for the motility of GBM cells. The western blot analysis substantiated that BNE acts on PTEN/PI3K/AKT signaling and the ERK1/2 pathway to impede the proliferation of Ln-229 cells. Moreover, BNE curtailed the migration and invasion of Ln-229 cells by targeting FAK/Src signaling and by downregulating MMP9 expression. In silico analysis, including docking studies and molecular dynamics simulations, further corroborated the interaction of selected target proteins with bixin.
conclusionTaking together, our findings revealed that bixin has therapeutic potential in mitigating GBM cell behavior by acting on multiple targets to limit its proliferation, migration, and invasion.
Indexed as
Identifiers
41961312What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.